Meta-analysis of microarray data identifies gas6 expression as an independent predictor of poor survival in ovarian cancer

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Buehler, Michelle ^a   Tse, Brian ^b   Leboucq, Alix ^c   Jacob, Francis ^a,b,d   Caduff, Rosmarie ^a   Fink, Daniel ^e   Goldstein, Darlene R ^c   Heinzelmann Schwarz, Viola ^a,b,d  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c EPFL   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITÄTSSPITAL ZÜRICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH ARREST SPECIFIC PROTEIN 6; TUMOR MARKER; GROWTH ARREST-SPECIFIC PROTEIN 6; SIGNAL PEPTIDE; TUMOR PROTEIN;

ADULT; AGED; ARTICLE; ASCITES; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER TISSUE; COHORT ANALYSIS; CYSTADENOMA; DISEASE SEVERITY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); MICROARRAY ANALYSIS; MINIMAL RESIDUAL DISEASE; OVARY CANCER; OVARY CARCINOMA; PREDICTIVE VALUE; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN MICROARRAY; RECURRENCE FREE SURVIVAL; TISSUE LEVEL; CHEMISTRY; EVIDENCE BASED MEDICINE; META ANALYSIS; MIDDLE AGED; MORTALITY; OVARY TUMOR; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; STATISTICS AND NUMERICAL DATA; SURVIVAL RATE; STATISTICS;

ADULT; AGED; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; NEOPLASM PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84880149965     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/238284     Document Type: Article

References (29)

1. Ries L. A., Eisner M. P., Kosary C. L., SEER Cancer Statistics Review, 1975-2000 2003
2. Bray F., Loos A. H., Tognazzo S., La Vecchia C., Ovarian cancer in Europe: cross-sectional trends in incidence and mortality in 28 countries, 1953-2000. International Journal of Cancer 2005 113 6 977 990 2-s2.0-11844278537 10.1002/ijc.20649
3. Russel P. J., Robboy S. J., Anderson M. C., Robboy S. J., Anderson M. C., Russel P. J., Ovarian tumors: classification and clinical perspective. Pathology of the Female Reproductive Tract 2002 London, UK Churchill Livingstone 527 538
4. Bast R. C. Jr., Xu F. J., Yu Y. H., Barnhill S., Zhang Z., Mills G. B., CA 125: the past and the future. International Journal of Biological Markers 1998 13 4 179 187 2-s2.0-0032425863
5. Russo G., Zegar C., Giordano A., Advantages and limitations of microarray technology in human cancer. Oncogene 2003 22 43 6497 6507 2-s2.0-0242405575
6. Lancaster J. M., Dressman H. K., Clarke J. P., Sayer R. A., Martino M. A., Cragun J. M., Henriott A. H., Gray J., Sutphen R., Elahi A., Whitaker R. S., West M., Marks J. R., Nevins J. R., Berchuck A., Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. International Journal of Gynecological Cancer 2006 16 5 1733 1745 2-s2.0-33749138460 10.1111/j.1525-1438.2006.00660.x
7. Schaner M. E., Ross D. T., Ciaravino G., Sørlie T., Troyanskaya O., Diehn M., Wang Y. C., Duran G. E., Sikic T. L., Caldeira S., Skomedal H., Tu I., Hernandez-Boussard T., Johnson S. W., O'Dwyer P. J., Fero M. J., Kristensen G. B., Børresen-Dale A., Hastie T., Tibshirani R., van de Rijn M., Teng N. N., Longacre T. A., Botstein D., Brown P. O., Sikic B. I., Gene expression patterns in ovarian carcinomas. Molecular Biology of the Cell 2003 14 11 4376 4386 2-s2.0-10744220410 10.1091/mbc.E03-05-0279
8. Schwartz D. R., Kardia S. L. R., Shedden K. A., Kuick R., Michailidis G., Taylor J. M. G., Misek D. E., Wu R., Zhai Y., Darrah D. M., Reed H., Ellenson L. H., Giordano T. J., Fearon E. R., Hanash S. M., Cho K. R., Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Research 2002 62 16 4722 4729 2-s2.0-0037102445
9. Dressman H. K., Berchuck A., Chan G., Zhai J., Bild A., Sayer R., Cragun J., Clarke J., Whitaker R. S., Li L., Gray J., Marks J., Ginsburg G. S., Potti A., West M., Nevins J. R., Lancaster J. M., An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer (Journal of Clinical Oncology (2007) 25 (517-525)). Journal of Clinical Oncology 2012 30 6 678 2-s2.0-84857508382 10.1200/JCO.2012.42.0331
10. Hutterer M., Knyazev P., Abate A., Reschke M., Maier H., Stefanova N., Knyazeva T., Barbieri V., Reindl M., Muigg A., Kostron H., Stockhammer G., Ullrich A., Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme. Clinical Cancer Research 2008 14 1 130 138 2-s2.0-40749123639 10.1158/1078-0432.CCR-07-0862
11. Sawabu T., Seno H., Kawashima T., Fukuda A., Uenoyama Y., Kawada M., Kanda N., Sekikawa A., Fukui H., Yanagita M., Yoshibayashi H., Satoh S., Sakai Y., Nakano T., Chiba T., Growth arrest-specific gene 6 and Axl signaling enhances gastric cancer cell survival via Akt pathway. Molecular Carcinogenesis 2007 46 2 155 164 2-s2.0-33847008999 10.1002/mc.20211
12. Sun W., Fujimoto J., Tamaya T., Coexpression of Gas6/Axl in human ovarian cancers. Oncology 2004 66 6 450 457 2-s2.0-5644239572 10.1159/000079499
13. Bellosta P., Zhang Q., Goff S. P., Basilico C., Signaling through the ARK tyrosine kinase receptor protects from apoptosis in the absence of growth stimulation. Oncogene 1997 15 20 2387 2397 2-s2.0-0030817336
14. 2+-mobilizing growth factors. The Journal of Biological Chemistry 1995 270 11 5702 5705 2-s2.0-0028943107 10.1074/jbc.270.11.5702
15. Fridell Y. C., Villa J. Jr., Attar E. C., Liu E. T., GAS6 induces Axl-mediated chemotaxis of vascular smooth muscle cells. The Journal of Biological Chemistry 1998 273 12 7123 7126 2-s2.0-0032549528 10.1074/jbc.273.12.7123
16. Wirapati P., Sotiriou C., Kunkel S., Farmer P., Pradervand S., Haibe-Kains B., Desmedt C., Ignatiadis M., Sengstag T., Schütz F., Goldstein D. R., Piccart M., Delorenzi M., Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Research 2008 10 4, article R65 2-s2.0-58149330982 10.1186/bcr2124
17. Hedges L. V., Olkin I., Statistical Methods for Meta-Analysis 1985 Orlando, Fla, USA Academic Press
18. Bellido-Martín L., de Frutos P. G., Vitamin K-dependent actions of Gas6. Vitamins and Hormones 2008 78 185 209 2-s2.0-40949097262 10.1016/S0083-6729(07)00009-X
19. Hafizi S., Dahlbäck B., Gas6 and protein S: vitamin K-dependent ligands for the Axl receptor tyrosine kinase subfamily. FEBS Journal 2006 273 23 5231 5244 2-s2.0-33751079330 10.1111/j.1742-4658.2006.05529.x
20. Nagata K., Ohashi K., Nakano T., Arita H., Zong C., Hanafusa H., Mizuno K., Identification of the product of growth arrest-specific gene 6 as a common ligand for Axl, Sky, and Mer receptor tyrosine kinases. The Journal of Biological Chemistry 1996 271 47 30022 30027 2-s2.0-0029910706 10.1074/jbc.271.47.30022
21. Craven R. J., Xu L., Weiner T. M., Fridell Y. W., Dent G. A., Srivastava S., Varnum B., Liu E. T., Cance W. G., Receptor tyrosine kinases expressed in metastatic colon cancer. International Journal of Cancer 1995 60 6 791 797 2-s2.0-0028900612 10.1002/ijc.2910600611
22. Ito T., Ito M., Naito S., Ohtsuru A., Nagayama Y., Kanematsu T., Yamashita S., Sekine I., Expression of the Axl receptor tyrosine kinase in human thyroid carcinoma. Thyroid 1999 9 6 563 567 2-s2.0-0033056516
23. Gjerdrum C., Tiron C., Høiby T., Stefansson I., Haugen H., Sandal T., Collett K., Li S., McCormack E., Gjertsen B. T., Micklem D. R., Akslen L. A., Glackin C., Lorens J. B., Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proceedings of the National Academy of Sciences of the United States of America 2010 107 3 1124 1129 2-s2.0-75749115996 10.1073/pnas.0909333107
24. Gustafsson A., Martuszewska D., Johansson M., Ekman C., Hafizi S., Ljungberg B., Dahlbäck B., Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival. Clinical Cancer Research 2009 15 14 4742 4749 2-s2.0-68049096311 10.1158/1078-0432.CCR-08-2514
25. Rankin E. B., Fuh K. C., Taylor T. E., Krieg A. J., Musser M., Yuan J., Wei K., Kuo C. J., Longacre T. A., Giaccia A. J., AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Research 2010 70 19 7570 7579 2-s2.0-77957375963 10.1158/0008-5472.CAN-10-1267
26. Hong C. C., Lay J. D., Huang J. S., Cheng A. L., Tang J. L., Lin M. T., Lai G. M., Chuang S. E., Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Letters 2008 268 2 314 324 2-s2.0-48549094691 10.1016/j.canlet.2008.04.017
27. Shiozawa Y., Pedersen E. A., Patel L. R., Ziegler A. M., Havens A. M., Jung Y., Wang J., Zalucha S., Loberg R. D., Pienta K. J., Taichman R. S., GAS6/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche. Neoplasia 2010 12 2 116 127 2-s2.0-76749109371 10.1593/neo.91384
28. Sainaghi P. P., Castello L., Bergamasco L., Galletti M., Bellosta P., Avanzi G. C., Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. Journal of Cellular Physiology 2005 204 1 36 44 2-s2.0-20144384673 10.1002/jcp.20265
29. Mc Cormack O., Chung W. Y., Fitzpatrick P., Cooke F., Flynn B., Harrison M., Fox E., Gallagher E., Goldrick A. M., Dervan P. A., Mc Cann A., Kerin M. J., Growth arrest-specific gene 6 expression in human breast cancer. The British Journal of Cancer 2008 98 6 1141 1146 2-s2.0-40849096161 10.1038/sj.bjc.6604260